Results 31 to 40 of about 76,723 (183)

Multimodal Autonomic Biomarkers Predict Phenoconversion in Pure Autonomic Failure

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Pure autonomic failure (PAF) presents with autonomic failure without other neurological features. A third develop central neurological features, fulfilling criteria for multiple system atrophy (MSA) and Lewy body diseases (LBD), including Parkinson's disease and Dementia with Lewy bodies.
S. Koay   +12 more
wiley   +1 more source

The Postural Tachycardia Syndrome (POTS): Pathophysiology, Diagnosis & Management [PDF]

open access: yes, 2006
Postural tachycardia syndrome (POTS), characterized by orthostatic tachycardia in the absence of orthostatic hypotension, has been the focus of increasing clinical interest over the last 15 years 1. Patients with POTS complain of symptoms of tachycardia,
Raj, Satish R
core   +1 more source

Exenatide Once Weekly in the Treatment of Patients with Multiple System Atrophy

open access: yesAnnals of Neurology, EarlyView.
Objective Exenatide, a glucagon‐like peptide‐1 (GLP‐1) receptor agonist, has neuroprotective effects in preclinical models of multiple system atrophy (MSA). We investigated these effects in a proof‐of‐concept clinical trial. Methods In this single‐center, randomized, open label trial, participants with MSA were randomly assigned (1:1) to receive ...
Nirosen Vijiaratnam   +29 more
wiley   +1 more source

Disease modifying therapy for multiple system atrophy – Parkinsonian Type [PDF]

open access: yes, 2017
BACKGROUND: Multiple System Atrophy –Parkinsonian Type (MSA-P) is a rare, rapidly progressive neurodegenerative disease without any current treatment.
Dwyer, Sean Sullivan
core  

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses and Dose Titration of Bexicaserin in Healthy Participants in a Randomized, Double‐Blind, Placebo‐Controlled Study

open access: yesClinical Pharmacology in Drug Development, EarlyView.
Abstract Bexicaserin (LP352) is a selective superagonist of the 5‐hydroxytryptamine 2C (5‐HT2C) receptor currently in development for the treatment of seizures that arise from developmental and epileptic encephalopathies. This phase 1, double‐blind, placebo‐controlled multiple ascending dose (MAD) study assessed the safety, tolerability, and ...
Jonathan Williams   +7 more
wiley   +1 more source

Locus Coeruleus Volume is Reduced in Early Parkinson Disease-Related Orthostatic Hypotension.

open access: yes, 2021
Background Orthostatic hypotension (OH) is common in Parkinson disease (PD) and often coincident with cognitive impairment. The locus coeruleus (LC), a central autonomic and cognitive regulator, may be a common pathophysiologic link.
P. Beach   +5 more
semanticscholar   +1 more source

The emergency department evaluation and outcomes of elderly fallers [PDF]

open access: yes, 2016
BACKGROUND: Approximately one-third of community dwelling elderly people (age ≥65 years) falls each year contributing to over 2 million elderly emergency department (ED) visits for falls annually.
Tirrell, Gregory
core   +1 more source

Post-Partum Pituitary Insufficiency and Livedo Reticularis Presenting a Diagnostic Challenge in a Resource Limited Setting in Tanzania: A Case Report, Clinical Discussion and Brief Review of Existing Literature. [PDF]

open access: yes, 2012
Pituitary disorders following pregnancy are an important yet under reported clinical entity in the developing world. Conversely, post partum panhypopituitarism has a more devastating impact on women in such settings due to high fertility rates, poor ...
A Cénac   +27 more
core   +3 more sources

Review of published research on primary dysautonomia of domestic animals

open access: yesVeterinary Record, EarlyView.
Abstract An article published in 1992 by Marion M. Pollin and I.R. Griffiths reviewed the topic of primary dysautonomias of the autonomic nervous system of unidentified origin in multiple domestic species, specifically cats, dogs and horses. Thirty‐one years later, we appear no closer to identifying the causal agents of these strikingly similar ...
Tanith Harte   +3 more
wiley   +1 more source

Pharmacokinetics and safety of eptinezumab in children and adolescents with migraine

open access: yesHeadache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective The primary objective was to characterize the pharmacokinetics (PK) and safety of eptinezumab in children and adolescents with migraine. Background Migraine in children and adolescents is a prevalent and potentially debilitating disease, and few preventive therapies are approved for use in these populations. Eptinezumab, a calcitonin
Andrew D. Hershey   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy